1月7日，百龙创园跌5.16%，截至发稿，报20.95元/股，成交1.02亿元，换手率1.14%，总市值87.99亿 元。 资料显示，山东百龙创园生物科技股份有限公司位于山东省德州(禹城)国家高新技术产业开发区德信大 街，成立日期2005年12月30日，上市日期2021年4月21日，公司主营业务涉及益生元系列产品、膳食纤 维系列产品、其他淀粉糖(醇)系列产品和健康甜味剂产品的研发、生产及销售。主营业务收入构成为： 膳食纤维系列54.15%，益生元系列28.00%，健康甜味剂13.57%，其他(补充)3.91%，其他淀粉糖 (醇)0.38%。 截至发稿，孙文龙累计任职时间10年353天，现任基金资产总规模22.44亿元，任职期间最佳基金回报 238.74%， 任职期间最差基金回报-2.98%。 从基金十大重仓股角度 数据显示，博道基金旗下1只基金重仓百龙创园。博道惠泰优选混合A（016840）三季度增持12.19万 股，持有股数487.99万股，占基金净值比例为4.36%，位居第四大重仓股。根据测算，今日浮亏损失约 556.31万元。 从百龙创园十大流通股东角度 数据显示，博道基金旗下1只基金位居百龙创园十大流 ...

来源：新浪证券-红岸工作室 1月5日，百龙创园涨1.16%，成交额1.44亿元，换手率1.56%，总市值91.77亿元。 异动分析 代糖概念+参股银行+人民币贬值受益+专精特新+海峡两岸 1、公司生产的健康甜味剂产品主要为阿洛酮糖，阿洛酮糖是在自然界中天然存在但含量极少的一种稀 有单糖，其甜味及口感与蔗糖相当类似或接近，但其热量却远低于蔗糖，对于肥胖以及糖尿病患者是一 种理想的蔗糖代替物。 2、2024年半年报，公司持有山东禹城农村商业银行股份有限公司 5.14%股份。 3、根据2024年年报，公司海外营收占比为60.62%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入362.27万，占比0.03%，行业排名33/181，该股当前无连续增减仓现象，主力趋势不明 显；所属行业主力净流入1.84亿，当前无连续增减仓现象，主力趋势不明显。 区间今日近3日近5日近10日近20日主力净流入362.27万-485.05万210.36万-2270.36万-3789.31万 主力持仓 4、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、 ...

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing positive market movements, with a recent stock price increase and significant revenue growth, driven by its innovative health sweetener products and strategic investments in the banking sector [1][8]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and health sweetener products, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other products [8]. - As of December 10, the company had 12,300 shareholders, an increase of 12.12% from the previous period, with an average of 34,216 circulating shares per shareholder, a decrease of 10.81% [8]. - The company was established on December 30, 2005, and went public on April 21, 2021, located in the Dezhou (Yucheng) National High-tech Industrial Development Zone [8]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 969 million yuan, representing a year-on-year growth of 18.10%, and a net profit attributable to shareholders of 265 million yuan, up 44.93% year-on-year [8]. - The company has distributed a total of 204 million yuan in dividends since its A-share listing, with 193 million yuan distributed over the past three years [9]. Group 3: Market Position and Strategic Advantages - The company produces allulose, a rare monosaccharide that serves as a low-calorie alternative to sucrose, making it ideal for individuals with obesity and diabetes [2]. - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, benefiting from the depreciation of the RMB [3][4]. - The company has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, which enhances its competitiveness and stability within the industry [4]. Group 4: Stock Market Activity - On December 17, the company's stock rose by 2.68%, with a trading volume of 100 million yuan and a turnover rate of 1.14%, leading to a total market capitalization of 8.862 billion yuan [1]. - The average trading cost of the stock is 20.54 yuan, with the stock price approaching a resistance level of 21.24 yuan, indicating potential for upward movement if this level is surpassed [7].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth in its health sweetener products, particularly allulose, and benefits from its stake in a rural commercial bank, as well as the depreciation of the RMB. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fibers, and health sweeteners, with a revenue composition of 54.15% from dietary fibers, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other products [8] - As of November 30, the company had 10,900 shareholders, a decrease of 18.48%, with an average of 38,364 circulating shares per shareholder, an increase of 22.67% [8] - The company was established on December 30, 2005, and went public on April 21, 2021 [8] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 969 million yuan, representing a year-on-year growth of 18.10%, and a net profit attributable to shareholders of 265 million yuan, up 44.93% year-on-year [8] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9] Group 3: Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China, indicating its strong market position and innovation capabilities [4] Group 4: Stock Performance and Trading Activity - On December 5, the company's stock rose by 0.24%, with a trading volume of 38.1953 million yuan and a turnover rate of 0.44%, bringing the total market capitalization to 8.631 billion yuan [1] - The average trading cost of the stock is 20.59 yuan, with recent buying activity noted, although the strength of this accumulation is weak [7]

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing a decline in stock price while benefiting from its unique product offerings and strategic investments, particularly in the context of the depreciating RMB and its recognition as a "specialized and innovative" enterprise. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fiber products, and healthy sweeteners, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from healthy sweeteners, and 3.91% from other products [8] - As of November 30, the company had 10,900 shareholders, a decrease of 18.48% from the previous period, with an average of 38,364 circulating shares per shareholder, an increase of 22.67% [8] - The company achieved a revenue of 969 million yuan in the first nine months of 2025, representing a year-on-year growth of 18.10%, and a net profit of 265 million yuan, up 44.93% year-on-year [8] Group 2: Market Position and Financials - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which may provide additional financial stability [3] - The overseas revenue accounts for 60.62% of total revenue, benefiting from the depreciation of the RMB [4] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9] Group 3: Investment Highlights - The company produces allulose, a rare monosaccharide that serves as a low-calorie alternative to sucrose, making it ideal for individuals with obesity and diabetes [2] - The company has been recognized as a "specialized and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong market focus and innovation capabilities [4] - The stock has seen a recent decline of 2.01% with a trading volume of 48.91 million yuan and a market capitalization of 8.61 billion yuan [1]

Core Viewpoint - The company reported strong financial performance for Q1-Q3 2025, with significant year-on-year growth in revenue and net profit, indicating robust demand for its products and effective cost management strategies [1][2]. Financial Performance - For Q1-Q3 2025, the company achieved revenue of 970 million yuan, a year-on-year increase of 18.1%, and a net profit attributable to shareholders of 260 million yuan, up 44.9% year-on-year [1]. - In Q3 alone, the company generated revenue of 320 million yuan, reflecting a year-on-year growth of 10.6% but a quarter-on-quarter decline of 4.8% [1]. - The net profit for Q3 was 95 million yuan, representing a year-on-year increase of 50.5% and a quarter-on-quarter increase of 7.3% [1]. Product Performance - The company's prebiotic product line generated revenue of 96 million yuan in Q3, up 17.9% year-on-year but down 8.6% quarter-on-quarter [2]. - Dietary fiber products achieved revenue of 170 million yuan, a year-on-year increase of 12.7% and a quarter-on-quarter decline of 4.9% [2]. - The health sweetener product line saw revenue of 43 million yuan, down 4.9% year-on-year but slightly up 0.1% quarter-on-quarter [2]. Profitability Metrics - The company reported a gross profit margin of 44.5% in Q3, an increase of 11.9 percentage points year-on-year and 3.2 percentage points quarter-on-quarter [2]. - The net profit margin for Q3 was 29.7%, up 7.9 percentage points year-on-year and 3.4 percentage points quarter-on-quarter [2]. Market Developments - D-Allulose received approval for use in China, marking a significant milestone for the company and the industry, as it opens up new market opportunities for synthetic biological materials [3]. - Major companies in the D-Allulose market include Bailong Chuangyuan, Sanyuan Biological, and Baolingbao, with Bailong Chuangyuan holding a significant market share [3]. Production Capacity Expansion - The company is expanding its production capabilities with projects such as a 30,000-ton soluble dietary fiber project and a 15,000-ton crystalline sugar project, which are set to enhance production scale and reduce costs [4]. - Ongoing projects include a functional sugar drying expansion and a smart factory project in Thailand, aimed at increasing international competitiveness and production efficiency [4]. New Product Development - The company has successfully developed new products such as differentiated crystalline fructose and resistant starch, enhancing its market competitiveness [4]. - High-end products like isomaltulose and crystalline fructose have been successfully mass-produced and recognized by customers, enriching the product portfolio [4]. Industry Outlook - The company is positioned as a leading player in the food additive sector, with a growing demand for dietary fibers and sugar substitutes like D-Allulose [5]. - Projected net profits for 2025-2027 are estimated at 350 million, 480 million, and 680 million yuan, respectively, indicating a positive growth trajectory [5].

Investment Rating - The investment rating for the company is "Buy" and it is maintained [8]. Core Insights - The company reported a revenue of 970 million yuan for the first three quarters of 2025, representing a year-on-year increase of 18.1%. The net profit attributable to shareholders reached 260 million yuan, up 44.9% year-on-year, and the net profit after deducting non-recurring gains and losses was also 260 million yuan, reflecting a 50.4% increase year-on-year. In Q3 alone, the company achieved a revenue of 320 million yuan, a 10.6% increase year-on-year but a 4.8% decrease quarter-on-quarter. The net profit for Q3 was 95 million yuan, up 50.5% year-on-year and 7.3% quarter-on-quarter [2][6]. Summary by Sections Financial Performance - For Q1-3 2025, the company achieved a total revenue of 970 million yuan, with a net profit of 260 million yuan, and a net profit after deducting non-recurring items also at 260 million yuan. Q3 revenue was 320 million yuan, with a net profit of 95 million yuan and a net profit after deducting non-recurring items of 93 million yuan [2][6]. Product Performance - The company's prebiotic series products generated a revenue of 96 million yuan in Q3, a year-on-year increase of 17.9% but a quarter-on-quarter decrease of 8.6%. The dietary fiber series products achieved a revenue of 170 million yuan, up 12.7% year-on-year but down 4.9% quarter-on-quarter. The health sweetener series products had a revenue of 43 million yuan, down 4.9% year-on-year but stable quarter-on-quarter. The gross profit margin for Q3 was 44.5%, an increase of 11.9 percentage points year-on-year and 3.2 percentage points quarter-on-quarter [12]. Market Developments - The approval of D-alloheptulose in July 2025 marks a significant milestone for the company, allowing it to enter the domestic market. This approval ends a five-year application process and positions the company as a leading player in the industry [12]. Production Capacity Expansion - The company is expanding its production capacity with projects such as a 30,000-ton soluble dietary fiber project and a 15,000-ton crystalline sugar project, both of which are set to enhance production scale and reduce costs. Additionally, the Thailand project is underway, aiming to boost international competitiveness [12]. New Product Development - The company has successfully developed new products such as differentiated crystalline fructose and resistant starch, enhancing its market competitiveness. High-end products like isomaltulose and crystalline fructose have been launched and are gaining market acceptance [12]. Future Profit Projections - The projected net profits for 2025, 2026, and 2027 are 350 million yuan, 480 million yuan, and 680 million yuan, respectively, supporting the "Buy" rating [12].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing a decline in stock price while benefiting from its unique product offerings and strategic investments, particularly in the context of the depreciating RMB and its recognition as a "specialized and innovative" enterprise. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fibers, and healthy sweeteners, with a revenue composition of 54.15% from dietary fibers, 28.00% from prebiotics, 13.57% from healthy sweeteners, and 3.91% from other products [8] - As of October 31, the company had 13,400 shareholders, an increase of 3.75% from the previous period, with an average of 31,274 circulating shares per shareholder, a decrease of 3.62% [8] - The company was established on December 30, 2005, and went public on April 21, 2021 [8] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 969 million yuan, representing a year-on-year growth of 18.10%, and a net profit attributable to shareholders of 265 million yuan, up 44.93% year-on-year [8] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9] Group 3: Market Position and Strategic Advantages - The company produces allulose, a rare monosaccharide that serves as a low-calorie sugar substitute, making it ideal for individuals with obesity and diabetes [2] - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which enhances its financial positioning [3] - The company benefits from a 60.62% share of overseas revenue, aided by the depreciation of the RMB [4] - The company has been recognized as a "specialized and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong market focus and innovation capabilities [4] Group 4: Stock Performance and Market Sentiment - On November 4, the company's stock fell by 1.02%, with a trading volume of 77.1354 million yuan and a turnover rate of 0.89%, resulting in a total market capitalization of 8.564 billion yuan [1] - The stock's average trading cost is 20.46 yuan, with the current price near a support level of 20.18 yuan, indicating potential volatility [7] - The main capital inflow for the day was negative at 2.5415 million yuan, with a continuous reduction in main capital over the past two days [5][6]

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., has shown significant growth in revenue and net profit, benefiting from its unique product offerings and market positioning in the sugar substitute sector. Group 1: Company Performance - For the period from January to September 2025, the company achieved operating revenue of 969 million yuan, representing a year-on-year growth of 18.10% [8] - The net profit attributable to the parent company was 265 million yuan, reflecting a year-on-year increase of 44.93% [8] - The company has a market capitalization of 8.497 billion yuan, with a trading volume of 167 million yuan and a turnover rate of 1.96% on October 31 [1] Group 2: Product and Market Positioning - The company specializes in health sweeteners, particularly allulose, which is a rare monosaccharide that closely resembles sucrose in taste but has significantly lower calories, making it ideal for obesity and diabetes patients [2] - The company has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [4] Group 3: Shareholding and Institutional Investment - As of September 30, 2025, the company held a 5.14% stake in Shandong Yucheng Rural Commercial Bank [3] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Penghua New Emerging Industries Mixed A, with some fluctuations in their holdings [10] Group 4: Revenue Composition - The company's main business revenue composition includes dietary fiber series (54.15%), prebiotic series (28.00%), health sweeteners (13.57%), and others (3.91%) [8]

Group 1 - The core point of the article highlights the recent performance of Bailong Chuangyuan, which saw a 5.09% increase in stock price, reaching 20.44 CNY per share, with a total market capitalization of 8.585 billion CNY [1] - Bailong Chuangyuan specializes in the research, production, and sales of prebiotic products, dietary fiber products, starch sugar (alcohol) products, and health sweeteners, with dietary fiber contributing 54.15% to revenue, prebiotics 28.00%, health sweeteners 13.57%, and others 3.91% [1] - The company is located in Dezhou, Shandong Province, and was established on December 30, 2005, with its listing date on April 21, 2021 [1] Group 2 - From the perspective of major shareholders, Baodao Fund's Hui Tai You Xuan Mixed A Fund increased its holdings in Bailong Chuangyuan by 121,900 shares in the third quarter, now holding 4.8799 million shares, which is 1.16% of the circulating shares [2] - The fund has achieved a year-to-date return of 27.75% and ranks 3442 out of 8154 in its category, with a total fund size of 778 million CNY [2] - The fund manager, Sun Wenlong, has a tenure of 10 years and 285 days, with the best fund return during his tenure being 238.74% [3] Group 3 - Bailong Chuangyuan is the fourth largest holding in the Baodao Hui Tai You Xuan Mixed A Fund, accounting for 4.36% of the fund's net value [4] - The fund's estimated floating profit from its investment in Bailong Chuangyuan is approximately 4.8311 million CNY [4]